Sonnet BioTherapeutics Holdings Inc. (NASDAQ:SONN) shares traded lower over the last trading session, losing 0.00% on 06/09/21. The shares fell to a low of $1.50 before closing at $1.53. Intraday shares traded counted 3.33 million, which was -208.73% lower than its 30-day average trading volume of 1.08M. SONN’s previous close was $1.53 while the outstanding shares total 21.07M. The firm has a beta of 0.67. The stock’s Relative Strength Index (RSI) is 40.51, with weekly volatility at 5.65% and ATR at 0.14. The SONN stock’s 52-week price range has touched low of $1.44 and a $7.89 high.
Investors have identified the Biotechnology company Sonnet BioTherapeutics Holdings Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $32.24 million, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
Sonnet BioTherapeutics Holdings Inc. (SONN) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. In terms of their assets, the company currently has 7.4 million total, with 5.4 million as their total liabilities.
SONN were able to record -10.77 million as free cash flow during the 08/12/2021 quarter of the year, this saw their quarterly net cash flow reduce by -0.61 million. In cash movements, the company had a total of -10.77 million as operating cash flow.
Is the stock of SONN attractive?
In related news, Chief Medical Officer, Kenney Richard T bought 15,000 shares of the companyâ€™s stock in a transaction that recorded on Jun 09. The purchase was performed at an average price of 1.54, for a total value of 23,100. As the purchase deal closes, the Chairman, President and CEO, Mohan Pankaj now bought 32,000 shares of the companyâ€™s stock, valued at 49,580. Also, Chief Medical Officer, Kenney Richard T bought 10,000 shares of the companyâ€™s stock in a deal that was recorded on May 19. The shares were cost at an average price of 1.55 per share, with a total market value of 15,500. In the last 6 months, insiders have changed their ownership in shares of company stock by 2.00%.